艾媒咨询 | 2025年中国创新药领域市场状况及标杆企业经营数据分析报告

在全球医药创新浪潮中，新的技术路径正深刻重塑产业投资格局，推动行业从传统仿制迈向原始创新。创新药行业凭借专利护城河与技术壁垒，日渐成为资本市场高度聚焦的黄金赛道。中国创新药在此背景下加速崛起，完成了从仿制跟随到全球引领的历史性跨越。高强度的研发投入与专利布局使得头部企业强者恒强，而技术路线的差异化则成为中小型药企弯道超车的可能路径。整体来看，创新药行业正处于政策、技术与资本共振的黄金发展期，但同时也伴随着高投入与高风险的固有属性。
全球领先的新经济产业第三方数据挖掘和分析机构iiMedia Research（艾媒咨询）最新发布的《2025年中国创新药领域市场状况及标杆企业经营数据分析报告》数据显示，创新药概念板块利润前三名企业依次为药明康德、恒瑞医药、复星医药。艾媒咨询分析师认为，板块盈利高度集中，前三名贡献TOP10企业超六成利润，行业整体盈利稳健，TOP10企业均实现盈利，但利润规模分化明显，反映出头部企业在研发、商业化及全球化方面的领先优势已转化为强劲的盈利能力；研发投入占营收比例前三名企业为首药控股-U、益方生物-U、海创药业-U，平均研发投入占比远超常规高科技行业水平，呈现出“营收未规模化，研发高强度投入”的早期创新特征，普遍反映了企业尚处研发驱动阶段，营收基数小导致占比畸高。这种不计短期盈利的大额投入是生物科技企业构建未来核心管线与竞争力的关键，但也伴随着高风险。

艾媒咨询 | 2025年中国病毒防治产业发展状况及重点企业大数据监测报告

当前，全球病毒变异迭代加速，公共卫生防控常态化需求持续凸显，叠加中国生物医药技术创新升级与政策精准赋能，病毒防治产业正迎来新一轮发展机遇与调整周期。全球领先的新经济产业第三方数据挖掘和分析机构iiMedia Research（艾媒咨询）最新发布的《2025年中国病毒防治产业发展状况及重点企业大数据监测报告》显示，2025年病毒防治产业集中度持续提升，营收前三名企业合计贡献TOP10整体营收的42.13%，研发投入累计投入达16.59亿元，头部引领效应凸显。细分领域中，以岭药业依托中药防治优势实现扭亏为盈，前三季度归母净利润实现10亿元，毛利率维持60%以上；华大基因深耕精准医学检测细分领域，前三季度营收规模超25亿元，市净率达2.29倍，展现出细分赛道的发展韧性。艾媒咨询分析师认为，2025年病毒防治产业处于调整转型期，研发创新、产品迭代及市场布局优化成为企业突破发展瓶颈、提升核心竞争力的关键，同时也将逐步筑牢公共卫生安全保障的产业根基，推动构建人类卫生健康共同体。
　　At present, the global iteration of virus variants is accelerating, and the demand for the normalization of public health prevention and control remains prominent. Coupled with the innovation and upgrading of China's biopharmaceutical technology and precise policy support, the virus prevention and control industry is ushering in a new round of development opportunities and adjustment cycle. According to the 2025 Report on the Development Status of China's Virus Prevention and Control Industry and Big Data Monitoring of Key Enterprises newly released by iiMedia Research, a world-leading third-party institution for data mining and analysis of the new economy industry, the concentration of the virus prevention and control industry continued to rise in 2025. The top three enterprises in terms of revenue contributed 42.13% of the total revenue of the top 10 enterprises combined, with a cumulative R&D investment of 1.659 billion yuan, highlighting the leading effect of head enterprises.
　　In the segmented sectors, Yiling Pharmaceutical turned losses into profits by virtue of its advantages in traditional Chinese medicine (TCM) prevention and control, achieving a net profit attributable to shareholders of listed companies of 1 billion yuan in the first three quarters with a gross profit margin maintained above 60%. BGI Genomics has deepened its layout in the segmented field of precision medical testing, recording a revenue scale of over 2.5 billion yuan in the first three quarters and a price-to-book ratio of 2.29 times, demonstrating the development resilience of the segmented track.
　　Analysts from iiMedia Research hold that the virus prevention and control industry is in a period of adjustment and transformation in 2025. R&D innovation, product iteration and optimization of market layout have become the key for enterprises to break through development bottlenecks and enhance core competitiveness. Meanwhile, this will gradually consolidate the industrial foundation for public health security and boost the building of a global community of health for all.